NCT02841267View on ClinicalTrials.gov

A Trial of PF-06252616 in Ambulatory Participants With LGMD2I

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

July 31, 2016

Primary Completion Date

January 31, 2019

Study Completion Date

January 31, 2019

Conditions
LGMD2I
Interventions
DRUG

PF 06252616

Trial Locations (1)

21205

Hugo W. Moser Research Institute at Kennedy Krieger, Inc., Baltimore

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Kathryn Wagner

OTHER

NCT02841267 - A Trial of PF-06252616 in Ambulatory Participants With LGMD2I | Biotech Hunter | Biotech Hunter